Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04682600Not ApplicableCompleted

The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF

Role: lead

NCT06218589Not ApplicableActive Not Recruiting

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

Role: collaborator

NCT07373769Not Yet Recruiting

Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease

Role: collaborator

NCT04576897Not ApplicableCompleted

Velacur by Sonic Incytes for Portal Hypertension

Role: collaborator

NCT04576923Not ApplicableTerminated

Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease

Role: collaborator

NCT05908006Unknown

Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease

Role: collaborator

NCT03957070Not ApplicableCompleted

The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis

Role: lead

All 7 trials loaded